30-60-90 Day Plan for a Fractional AI Lead in a Healthcare Startup

TL;DR

The fractional AI lead must deliver a data‑driven product roadmap within 30 days, validate clinical impact by day 60, and secure stakeholder buy‑in with a measurable AI strategy by day 90. Failure to do so signals a mismatch between ambition and execution capacity.

Who This Is For

You are a senior AI professional negotiating a part‑time (≤30 h / week) leadership contract at a seed‑stage health‑tech venture that has raised $12 M, employs 22 people, and expects its first FDA‑cleared AI module within 12 months. You already command $180k–$220k base plus $30k–$50k equity, and you need a concrete onboarding plan to convince the founding team you can move the needle quickly.

How should a fractional AI lead prioritize the first 30 days?

The priority is to map the data‑pipeline and align on a single “clinical‑value hypothesis” that can be tested in 90 days. In the Q1 debrief, the CTO slammed the candidate for spending two weeks cataloguing data sources without surfacing a clear hypothesis; the hiring committee then demanded a “hypothesis‑first” approach. The first 30‑day sprint therefore consists of three deliverables: (1) an audited inventory of all structured and unstructured health data (EHR, imaging, wearables), (2) a stakeholder‑validated hypothesis document that ties a specific AI output to a measurable clinical outcome (e.g., 15 % reduction in readmission risk), and (3) a lean proof‑of‑concept (PoC) scope that can be executed within 4 weeks.

Not “just data collection, but hypothesis‑driven design” is the correct lens. The not‑X‑but‑Y contrast clarifies that the problem isn’t the volume of data you ingest — it’s the signal you extract. The framework used here is the “Three‑Phase Alignment Model”: (i) Data Audit, (ii) Clinical Hypothesis, (iii) PoC Scope. Executing this model forces you to treat every data source as a potential experiment rather than a static asset.

What metrics must be established by day 60?

By day 60 the lead must present three validated metrics: (1) model performance (AUROC ≥ 0.78 on a hold‑out clinical cohort), (2) operational latency (≤ 2 seconds inference for bedside decision support), and (3) regulatory readiness (drafted 510(k) pre‑submission checklist). In the hiring manager’s interview, the VP of Clinical Ops asked for a concrete “impact‑scorecard” and the candidate responded with a spreadsheet showing each metric, the target, and the owner. That script convinced the panel that the candidate could translate technical work into business‑level KPIs.

The not‑X‑but‑Y insight is that the metric isn’t “model accuracy” alone; it’s “clinical relevance + deployment feasibility.” The counter‑intuitive truth is that a model with an AUROC of 0.82 but a 10‑second inference time will be rejected in favor of a 0.76 model that runs in 1 second, because the latter meets workflow constraints. This principle reflects an organizational psychology rule: “People adopt technology that fits existing habits, not the one that promises higher performance on paper.”

How does a fractional AI lead communicate impact to investors at day 90?

The communication must be a concise, data‑backed narrative that ties the AI PoC to revenue forecasts and regulatory milestones. In a board‑room update on day 90, the candidate opened with “Our AI module will shave 15 % readmission risk, translating to $2.3 M ARR by Q4 2025” and then walked through a slide deck that showed the three‑metric scorecard, the risk‑adjusted ROI model, and a timeline to FDA 510(k) clearance. The script used the phrase “From hypothesis to validated product in 90 days” and secured a $1 M bridge round earmarked for scaling the AI pipeline.

The not‑X‑but Y contrast here is that the impact isn’t “technical novelty” but “tangible financial upside.” The judgment is that investors care about dollars, not algorithms. The insight layer is the “Value‑Bridge Framework” that maps technical deliverables to financial levers: (i) risk reduction → cost avoidance, (ii) speed to market → revenue acceleration, (iii) compliance → funding eligibility.

Which stakeholder relationships are non‑negotiable for a fractional AI lead?

The non‑negotiable relationships are with (1) the Chief Medical Officer (clinical validation), (2) the Head of Data Engineering (data ingestion), and (3) the Compliance Officer (regulatory pathway). In the final interview, the hiring committee asked the candidate to role‑play a meeting with the CMO where she must obtain consent to pilot the AI model on two ICU units. The candidate’s reply—“We will co‑design the protocol, share weekly safety dashboards, and align success criteria with your quality metrics”—earned a unanimous yes.

The not‑X‑but Y distinction is that the relationship isn’t “friendly networking,” it’s “strategic co‑ownership of outcomes.” The counter‑intuitive observation is that a fractional lead who spends the first two weeks building a Slack channel with engineers will fail faster than one who spends three days drafting a joint clinical‑validation charter. This follows the “Stakeholder‑Ownership Principle”: only those who own the risk can champion the solution.

What governance structures should be set up in the first quarter?

The governance structure must consist of a weekly “AI Steering Committee” chaired by the CTO, a bi‑weekly “Clinical Review Board” chaired by the CMO, and a quarterly “Regulatory Milestone Review” led by the Compliance Officer. In the debrief after the interview loop, the hiring manager argued that without a formal governance cadence the AI lead would become a “solo cowboy,” which the interview panel rejected. The resulting governance model forces transparency, aligns incentives, and creates a documented audit trail for FDA reviewers.

The not‑X‑but Y contrast is that governance isn’t “paperwork for compliance” but “continuous risk mitigation.” The insight is that a “tri‑layered oversight” reduces the probability of a regulatory surprise from 30 % to under 5 % according to internal risk logs. The judgment is that without this structure the fractional lead will be forced out by the board in the next funding round.

Preparation Checklist

Review the startup’s data‑asset inventory (EHR schemas, DICOM storage, wearable APIs).
Draft a hypothesis‑validation brief (clinical outcome, target improvement, stakeholder sign‑off).
Map out a 30‑day PoC plan with milestones and owners.
Prepare a “Metrics‑Scorecard” template (AUROC, latency, regulatory checklist).
Create a stakeholder charter (CMO, Data Eng, Compliance) with joint success metrics.
Schedule the first AI Steering Committee meeting (include agenda and decision log).
Work through a structured preparation system (the PM Interview Playbook covers “Healthcare AI hypothesis framing” with real debrief examples).

Mistakes to Avoid

BAD: “Spend the first two weeks building a fancy model without a clinical hypothesis.” GOOD: “Validate the hypothesis with clinicians before any code is written.”

BAD: “Report only AUROC as a success metric.” GOOD: “Pair AUROC with latency and compliance readiness to reflect real‑world constraints.”

BAD: “Treat governance as optional paperwork.” GOOD: “Implement a tri‑layered review process from day 1 to satisfy regulators and investors.”

FAQ

What if the data audit reveals missing critical variables?

The judgment is to renegotiate scope immediately; you cannot fabricate data, but you can pivot the hypothesis to a proxy that still meets clinical relevance.

How much equity is reasonable for a fractional AI lead in a $12 M seed round?

A fair range is 0.15 %–0.30 % fully‑diluted, with vesting aligned to regulatory milestones; not a flat 0.5 % grant, but a performance‑linked tranche.

Can I deliver a 90‑day plan if I’m only 20 hours per week?

Yes, if you focus on hypothesis‑first design and delegate data engineering to the existing team; not “do everything yourself,” but “orchestrate the ecosystem.”

Ready to build a real interview prep system?

Get the full PM Interview Prep System →

The book is also available on Amazon Kindle.